Handbook of Cannabis Therapeutics by Grotenhermen Franjo. Russo Ethan

Author:Grotenhermen, Franjo.,Russo, Ethan.
Language: eng
Format: epub
Publisher: Taylor & Francis (CAM)

Update

Ethan B. Russo

This therapeutic area is one of extreme interest at the current time, as it has become increasingly apparent that the endocannabinoid system is one of many regulators/modulators of appetite and feeding behavior throughout the life span.

Dr. Fride has updated her own work (Fride et al. 2005), and an additional current review (Di Marzo and Matias 2005) that advocates the concept of an overactive endocannabinoid system in obesity is most helpful. The drug SR141716A (Rimonabant/Acomplia) is in advanced Phase III clinical trials for the indication of weight loss (Le Fur 2004), but phytocannabinoids such as cannabidiol (CBD)(Pertwee 2004) and tetrahydrocannabivarin (THCV) (Pertwee et al. 2004) may also be clinically applicable.

Further investigation reveals that serum anandamide levels are elevated in anorexia nervosa patients and binge eaters, but not those with bulimarexia (Monteleone et al. 2005). It is apparent that a great deal of practically useful information of clinical value will result from this research in the near future.

References

Di Marzo, V., and I. Matias. 2005. Endocannabinoid control of food intake and energy balance. Nat Neurosci 8 (5):585–589.

Fride, E., T. Bregman, and T.C. Kirkham. 2005. Endocannabinoids and food intake: Newborn suckling and appetite regulation in adulthood. Exp Biol Med (May-wood) 230 (4):225–234.

Le Fur, G. 2004. Clinical results with Rimonabant in obesity. Paper read at Conference on the Cannabinoids, June 25, Paestum, Italy.

Monteleone, P., I. Matias, V. Martiadis, L. De Petrocellis, M. Maj, and V. Di Marzo. 2005. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsycho-pharmacology 30(6):1216–1221.

Pertwee, R.G. 2004. The pharmacology and therapeutic potential of cannabidiol. In V. Di Marzo (ed.), Cannabinoids (pp. 32–83). Dordrecht, Netherlands: Kluwer Academic Publishers.

Pertwee, R.G., L.A. Stevenson, R.A. Ross, M.R. Price, K.N. Wease, and A. Thomas. 2004. The phytocannabinoid, THCV, potently antagonizes WIN55212–2 and anandamide in the mouse isolated vas deferens. In Proceedings of the British Pharmacology Society: Abstract P1. British Pharmacology Society.

Download

Copyright Disclaimer:
This site does not store any files on its server. We only index and link to content provided by other sites. Please contact the content providers to delete copyright contents if any and email us, we'll remove relevant links or contents immediately.